Smartkarma: ECM Coverage Weekly Update (28 July 2018)
The Smartkarma ECM Team puts out a weekly update on the deals we have covered recently, along with updates for upcoming IPOs. Pinduoduo (PDD US)...
619 Views
Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)
Corrigenda: There is an error in this insight, please note the correction. Correction: The drug name Conbercept has been misspelt as...
847 Views
Ascletis Pharma (1672 HK) IPO: First in Line
Ascletis Pharma is the first pharmaceutical company to file for an IPO in Hong Kong after the government allowed pre-revenue biotech companies to...
753 Views
Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)
In our last Insight covering Ascletis Pharma (Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market ), we discuss the...
535 Views
Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation
Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...
731 Views